| Trial watch: the clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors J Tang, JX Yu, VM Hubbard-Lucey, ST Neftelinov, JP Hodge, Y Lin Nature reviews Drug discovery, 854-856, 2018 | 359 | 2018 |
| Immuno-oncology drug development goes global JX Yu, VM Hubbard-Lucey, J Tang Nat Rev Drug Discov 18 (12), 899-900, 2019 | 237 | 2019 |
| Trends in clinical development for PD-1/PD-L1 inhibitors [J] N Durvalumab Nature reviews| Drug Discovery 19, 163, 2020 | 193 | 2020 |
| Impact of COVID-19 on oncology clinical trials S Upadhaya, JX Yu, C Oliva, M Hooton, J Hodge, VM Hubbard-Lucey Nat Rev Drug Discov 19 (6), 376-377, 2020 | 143 | 2020 |
| Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial LJ Padrón, DM Maurer, MH O’Hara, EM O’Reilly, RA Wolff, ZA Wainberg, ... Nature medicine 28 (6), 1167-1177, 2022 | 140 | 2022 |
| Combinations take centre stage in PD1/PDL1 inhibitor clinical trials. S Upadhaya, ST Neftelino, JP Hodge, C Oliva, JR Campbell, JX Yu Nature Reviews Drug Discovery 20 (3), 168-170, 2021 | 120 | 2021 |
| The global pipeline of cell therapies for cancer JX Yu, VM Hubbard-Lucey, J Tang Nat Rev Drug Discov 18 (11), 821-822, 2019 | 104 | 2019 |
| Immuno-oncology drug development forges on despite COVID-19 S Upadhaya, VM Hubbard-Lucey, JX Yu Nat Rev Drug Discov 19 (11), 751-2, 2020 | 91 | 2020 |
| Cancer cell therapies: the clinical trial landscape JX Yu, S Upadhaya, R Tatake, F Barkalow, VM Hubbard-Lucey Nat Rev Drug Discov 19 (9), 583-4, 2020 | 87 | 2020 |
| CRI iAtlas: an interactive portal for immuno-oncology research JA Eddy, V Thorsson, AE Lamb, DL Gibbs, C Heimann, JX Yu, V Chung, ... F1000Research 9, 2020 | 37 | 2020 |
| Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors Y Abdou, A Goudarzi, JX Yu, S Upadhaya, B Vincent, LA Carey NPJ Breast Cancer 8 (1), 121, 2022 | 32 | 2022 |
| RNA-Seq identifies SPGs as a ventral skeletal patterning cue in sea urchins ML Piacentino, DT Zuch, J Fishman, S Rose, EE Speranza, C Li, J Yu, ... Development 143 (4), 703-714, 2016 | 31 | 2016 |
| The clinical pipeline for cancer cell therapies S Upadhaya, JX Yu, M Shah, D Correa, T Partridge, J Campbell Nat Rev Drug Discov 20 (7), 503-504, 2021 | 30 | 2021 |
| COVID-19 impact on oncology clinical trials: a 1-year analysis. S Upadhaya, JX Yu, J Hodge, J Campbell Nat Rev Drug Discov, 415-415, 2021 | 27 | 2021 |
| Phenotype-based screens with conformation-specific inhibitors reveal p38 gamma and delta as targets for HCC polypharmacology JX Yu, AJ Craig, ME Duffy, C Villacorta-Martin, V Miguela, ... Molecular cancer therapeutics 18 (9), 1506-1519, 2019 | 21 | 2019 |
| Zygotic LvBMP5-8 is required for skeletal patterning and for left–right but not dorsal–ventral specification in the sea urchin embryo ML Piacentino, O Chung, J Ramachandran, DT Zuch, J Yu, EA Conaway, ... Developmental biology 412 (1), 44-56, 2016 | 11 | 2016 |
| 343 Multiomic biomarker signatures identify subsets of patients who may benefit from either nivolumab or sotigalimab in combination with chemotherapy in metastatic pancreatic … D Maurer, JX Yu, K Sklodowski, M Tognetti, L Reiter, R Bruderer, ... Journal for ImmunoTherapy of Cancer 9 (Suppl 2), 2021 | | 2021 |
| CRI iAtlas: an interactive portal for immuno-oncolog y research [version 1; peer review: 1 approved] JA Eddy, V Thorsson, AE Lamb, DL Gibbs, C Heimann, JX Yu, V Chung, ... | | 2020 |
